Aurinia Pharmaceuticals (AUPH) Resumen de Acciones
Aurinia Pharmaceuticals Inc, empresa biofarmacéutica, se dedica a suministrar terapias a personas que padecen enfermedades autoinmunes con grandes necesidades médicas no cubiertas en Estados Unidos y Japón. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 5/6 |
| Crecimiento futuro | 0/6 |
| Rendimiento pasado | 5/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
AUPH Community Fair Values
Create NarrativeSee what 30 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$21
FV
23.0% infravalorado descuento intrínseco15.00%
Revenue growth p.a.
93
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Competidores de Aurinia Pharmaceuticals Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$16.17 |
| Máximo en las últimas 52 semanas | US$19.25 |
| Mínimo de 52 semanas | US$10.34 |
| Beta | 1.4 |
| Cambio en 1 mes | 6.03% |
| Variación en 3 meses | 4.66% |
| Cambio de 1 año | 34.64% |
| Variación en 3 años | 74.25% |
| Variación en 5 años | -1.64% |
| Variación desde la OPV | 688.78% |
Noticias y actualizaciones recientes
Seeking Alpha • Aug 12
Aurinia Pharmaceuticals Doubles Down On Its Pipeline
Summary Aurinia Pharmaceuticals is running the phase 4 PRESERVE trial in lupus nephritis, which tests combinations containing the company's drug Lupkynis. Lupkynis could face potential challenges to its market exclusivity in the not-too-distant future. AUPH is developing aritinercept in four potential indications but doesn't provide much clarity on timelines for further updates. AUPH's acquisition of Kezar Life Sciences brought in a new drug, but it is not clear what AUPH plans to do with that drug. Read the full article on Seeking Alpha
Actualización de narrativa • Jul 17
Aritinercept Advances, but Commercialization Remains a 2030s Story
Aritinercept: Development Timeline and Key Milestones Aritinercept is Aurinia Pharmaceuticals’ emerging autoimmune asset, built around a dual BAFF/APRIL inhibition mechanism intended to modulate B‑cell activity. While still early in development, the program has progressed enough that investors can begin to outline a realistic timeline toward potential market entry.Actualización de narrativa • Jul 11
Lupus Nephritis Market Expansion: Implications for Aurinia Pharmaceuticals
The lupus nephritis (LN) market continues to evolve into one of the most important segments within autoimmune therapeutics. Rising disease prevalence, earlier diagnosis, and a shift toward targeted, steroid‑sparing treatments are reshaping expectations for companies operating in this space.Nueva narrativa • Jul 09
Aurinia Pharmaceuticals: Focused Execution in a Narrow but Durable Niche
Aurinia Pharmaceuticals (NASDAQ: AUPH) continues to prove that clarity can outperform complexity. With Lupkynis (voclosporin) as its single commercial asset for lupus nephritis , the company has turned concentration into discipline.Recent updates
Seeking Alpha • Aug 12
Aurinia Pharmaceuticals Doubles Down On Its Pipeline
Summary Aurinia Pharmaceuticals is running the phase 4 PRESERVE trial in lupus nephritis, which tests combinations containing the company's drug Lupkynis. Lupkynis could face potential challenges to its market exclusivity in the not-too-distant future. AUPH is developing aritinercept in four potential indications but doesn't provide much clarity on timelines for further updates. AUPH's acquisition of Kezar Life Sciences brought in a new drug, but it is not clear what AUPH plans to do with that drug. Read the full article on Seeking AlphaActualización de narrativa • Jul 17
Aritinercept Advances, but Commercialization Remains a 2030s Story
Aritinercept: Development Timeline and Key Milestones Aritinercept is Aurinia Pharmaceuticals’ emerging autoimmune asset, built around a dual BAFF/APRIL inhibition mechanism intended to modulate B‑cell activity. While still early in development, the program has progressed enough that investors can begin to outline a realistic timeline toward potential market entry.Actualización de narrativa • Jul 11
Lupus Nephritis Market Expansion: Implications for Aurinia Pharmaceuticals
The lupus nephritis (LN) market continues to evolve into one of the most important segments within autoimmune therapeutics. Rising disease prevalence, earlier diagnosis, and a shift toward targeted, steroid‑sparing treatments are reshaping expectations for companies operating in this space.Nueva narrativa • Jul 09
Aurinia Pharmaceuticals: Focused Execution in a Narrow but Durable Niche
Aurinia Pharmaceuticals (NASDAQ: AUPH) continues to prove that clarity can outperform complexity. With Lupkynis (voclosporin) as its single commercial asset for lupus nephritis , the company has turned concentration into discipline.
Actualización de narrativa • Jun 24
AUPH: Future Rerating Will Rely On Autoimmune Pipeline Expansion
Analysts have kept their fair value estimate for Aurinia Pharmaceuticals unchanged at $20.85 per share, making only modest adjustments to assumptions on the discount rate, revenue growth, profit margin, and future P/E based on recent peer takeover valuations and updated Street research. What's in the News for Aurinia Pharmaceuticals Aurinia Pharmaceuticals stock rose 6.5% on higher-than-average trading volume, with investors focused on growth potential beyond lead drug Lupkynis, according to recent coverage citing a P/E of 7.24 and a sector valuation ranking of 288 out of 388 (source: Zacks / recent news reports).Artículo de análisis • Jun 17
Aurinia Pharmaceuticals (AUPH) Stock Could Be 4.6% Undervalued After New LUPKYNIS Phase 3 Data
Aurinia Pharmaceuticals (AUPH) is back in focus after presenting new AURORA 1 Phase 3 data at the EULAR 2026 Congress, highlighting LUPKYNIS outcomes in adults with lupus nephritis. See our latest analysis for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals stock has gained momentum recently, with a 30 day share price return of 6.15% and a 90 day share price return of 15.20%. The 1 year total shareholder return of 105.06% and 3 year total shareholder return of 69.49% point to strong longer...
Actualización de narrativa • Jun 05
AUPH: Kidney Outcomes Data And Capital Moves Will Shape Balanced 2026 Outlook
Analysts now see Aurinia Pharmaceuticals' fair value holding steady at $17.00 per share, with a slightly lower discount rate and marginally adjusted revenue growth, profit margin, and future P/E assumptions supporting the updated target range following recent sector M&A comparisons. What's in the News LUPKYNIS data from the AURORA 1 Phase 3 study presented at the EULAR 2026 Congress show a statistically significant 53% reduction in risk of renal related events or death for lupus nephritis patients, with additional signals on death, treatment failure, and worsening proteinuria, according to the new analysis.Actualización de narrativa • May 21
AUPH: Future Rerating Will Rely On Sector Takeout Benchmarks
Narrative Update on Aurinia Pharmaceuticals Analysts now frame Aurinia Pharmaceuticals with a slightly revised price target of about $20.85 from $21.00, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E after reviewing recent sector takeout valuations. Analyst Commentary Recent commentary links Aurinia Pharmaceuticals to broader sector M&A activity, with bullish analysts pointing to the Kezar Life Sciences takeover valuation as a useful reference point for what acquirers have been willing to pay for comparable assets.Artículo de análisis • May 15
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Performance Raises Some Questions
We didn't see Aurinia Pharmaceuticals Inc.'s ( NASDAQ:AUPH ) stock surge when it reported robust earnings recently. We...Actualización de narrativa • May 05
AUPH: Sector Deal Benchmarks And 2026 Outlook Will Support Balanced Case
Analysts maintained their $17.00 price target for Aurinia Pharmaceuticals, citing updated model inputs and recent sector deal activity as supporting factors for their view of the stock’s current valuation. Analyst Commentary Bullish Takeaways Bullish analysts point to the Kezar Life Sciences takeover valuation as a helpful reference point, suggesting that recent transaction pricing in the sector supports the maintained US$17.00 target for Aurinia Pharmaceuticals.
Actualización de narrativa • Apr 20
AUPH: Future Returns Will Depend On Execution And Disciplined Takeover Multiples
Analysts have kept their fair value estimate for Aurinia Pharmaceuticals steady at $15.00. They cite updated modeling that slightly adjusts the discount rate, revenue growth outlook, profit margin assumptions, and forward P/E multiple in light of recent peer takeover valuations in the biotech space.Actualización de narrativa • Apr 06
AUPH: Richer Future P/E Will Rely On Executing Post Takeover Hopes
Analysts have raised their price target on Aurinia Pharmaceuticals to $15.00 from $13.00, citing updated views on fair value, discount rate, revenue growth, profit margin, and future P/E, informed in part by recent takeover valuation discussions in the sector. Analyst Commentary Analysts highlighting the recent Kezar Life Sciences takeover discussion point out that the implied valuation framework is one reference point for Aurinia Pharmaceuticals, but not a firm roadmap.Actualización de narrativa • Mar 23
AUPH: Stable 2026 Outlook And Buyback Progress Will Support Bullish Case
Analysts have kept their $17.00 price target for Aurinia Pharmaceuticals essentially unchanged, citing stable assumptions around the discount rate, revenue growth, profit margin, and future P/E as the basis for maintaining their view. What's in the News Aurinia issued earnings guidance for 2026, projecting total revenue in a range of $315 million to $325 million.Actualización de narrativa • Mar 08
AUPH: Higher 2026 Outlook And Margin Assumptions Will Support Bullish Case
Analysts have nudged their fair value estimate for Aurinia Pharmaceuticals from $16.67 to $17.00, reflecting updated assumptions around a slightly lower revenue growth outlook, a modestly higher profit margin, a small adjustment to the discount rate, and a higher future P/E multiple. What's in the News Aurinia issued 2026 earnings guidance, with total revenue expected in a range of $315 million to $325 million, and net product sales projected between $305 million and $315 million, both framed relative to 2025 levels (Key Developments).Actualización de narrativa • Feb 22
AUPH: Richer Future P/E Will Heighten Risk From Lower Profitability
Analysts have raised their fair value estimate for Aurinia Pharmaceuticals from $9.00 to $13.00 per share, citing updated assumptions that combine a higher projected revenue growth rate with a richer future P/E multiple and a lower expected profit margin profile. Valuation Changes Fair Value: increased from $9.00 to $13.00 per share, representing a sizeable uplift in the intrinsic value estimate.Actualización de narrativa • Feb 08
AUPH: Refined Discount Rate And Margins Will Support More Constructive Outlook
Analysts have adjusted their price target for Aurinia Pharmaceuticals to US$16.67. The updated view reflects slightly higher discount rate and profit margin assumptions, along with a modest tweak to projected revenue growth and future P/E.Actualización de narrativa • Jan 25
AUPH: Future Rerating Will Hinge On Aritinercept Development Clarity
Analysts have modestly increased their price target on Aurinia Pharmaceuticals to $15, up from $9, citing stronger than expected Lupkynis sales, improved operating leverage, and a desire for more clarity around aritinercept's development path before taking a more aggressive stance. Analyst Commentary Recent research reflects a more balanced stance on Aurinia Pharmaceuticals, even as the official price target is now set at $15, compared with the prior $9 level.Actualización de narrativa • Jan 10
AUPH: Higher Fair Value View Will Hinge On Lupus Nephritis Franchise
Analysts have raised their price target on Aurinia Pharmaceuticals from $16.46 to $21.00, reflecting updated assumptions on growth, profitability, and future P/E. They also highlight Lupkynis performance and the recent shift to a Sector Perform rating as key context for the revised outlook.Actualización de narrativa • Dec 17
AUPH: Legal Overhang And Pipeline Clarity Will Shape Balanced Near-Term Outlook
Analysts have nudged their fair value estimate for Aurinia Pharmaceuticals slightly higher to about $16.67 from $16.50, citing stronger than anticipated Lupkynis sales, improved operating leverage, and a more balanced risk reward profile that tempers the prior upside skew. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Lupkynis sales have materially outperformed initial expectations, reinforcing confidence in the durability of the core nephrology franchise and supporting higher revenue run rate assumptions.Actualización de narrativa • Dec 03
AUPH: Legal Overhang And Pipeline Uncertainty Will Likely Define Near-Term Performance
Analysts have modestly increased their price target on Aurinia Pharmaceuticals to approximately $16.50 per share from around $15.00, citing stronger than expected Lupkynis sales, improved operating leverage, and a more balanced risk reward profile, while noting that some caution is still warranted until there is greater clarity on aritinercept's development path. Analyst Commentary Recent commentary reflects a more balanced stance on Aurinia Pharmaceuticals, with valuation catching up to improving fundamentals and leaving less room for multiple expansion without new catalysts.Actualización de narrativa • Nov 19
AUPH: Risk And Opportunity Dynamics Will Likely Shape Performance Heading Into 2025
Narrative Update on Aurinia Pharmaceuticals Analysts have raised their price target for Aurinia Pharmaceuticals from $13 to $16.50 per share. They cite continued strong Lupkynis sales and improved operating leverage as key factors behind the increased valuation.Artículo de análisis • Nov 08
Improved Revenues Required Before Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock's 27% Jump Looks Justified
Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) shareholders have had their patience rewarded with a 27% share price jump...Actualización de narrativa • Nov 05
AUPH: Future Opportunities Will Depend On Pipeline Clarity And Risk Developments
Analysts have raised their fair value price target for Aurinia Pharmaceuticals from $11.71 to $13.00. They cite stronger-than-expected Lupkynis sales and improved profit margins as key factors supporting this upward revision.Artículo de análisis • May 19
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Strong Earnings Are Of Good Quality
The subdued stock price reaction suggests that Aurinia Pharmaceuticals Inc.'s ( NASDAQ:AUPH ) strong earnings didn't...Artículo de análisis • May 15
Aurinia Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) just released its latest quarterly results and things are looking bullish...Artículo de análisis • May 09
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) CEO Will Probably Find It Hard To See A Huge Raise This Year
Key Insights Aurinia Pharmaceuticals to hold its Annual General Meeting on 15th of May CEO Peter Greenleaf's total...
Nueva narrativa • Apr 28
Academic Medical Centers Will Expand Lupus Care Opportunities
Expansion into medical centers and new treatment guidelines may drive higher prescriber engagement and revenue for LUPKYNIS.Seeking Alpha • Apr 26
Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth
Summary AUPH has seen some management changes, but activist investors demand more despite steady Lupkynis sales growth. The first quarter was strong in terms of sales in 2023 and 2024, and upcoming Q1 '25 earnings represent an opportunity to confirm that trend. AUPH is also expected to report the first clinical data from AUR200 in Q2 '25, which might allow the opportunity for the company to one day grow beyond revenues from Lupkynis. Read the full article on Seeking AlphaArtículo de análisis • Apr 01
Little Excitement Around Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Revenues
Aurinia Pharmaceuticals Inc.'s ( NASDAQ:AUPH ) price-to-sales (or "P/S") ratio of 4.7x might make it look like a buy...Artículo de análisis • Mar 02
Results: Aurinia Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) last week reported its latest annual results, which makes it a good time...Seeking Alpha • Feb 21
Aurinia Pharmaceuticals: There's Still Time For Sales Growth
Summary AUPH's Lupkynis showed modest revenue growth from Q2'24 to Q3'24, but limited sales growth going from Q2 to Q3 has been seen previously. Full-year 2024 net product revenue guidance of $210M-$220M appears achievable, with $158.6M already reported and Q4 typically outperforming Q3. Potential competitors in lupus nephritis and even in systemic lupus erythematosus include Roche and Biogen. Read the full article on Seeking AlphaArtículo de análisis • Dec 11
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Held Back By Insufficient Growth Even After Shares Climb 25%
Despite an already strong run, Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) shares have been powering on, with a gain...Seeking Alpha • Nov 08
Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon
Summary Today, we are following up on biopharma name Aurinia Pharmaceuticals Inc. The company just posted solid Q3 results this week and announced significant cost reduction measures. Aurinia is seeing impressive sales growth, has a pristine balance sheet and should become increasingly profitable in coming years. The actions the company is taking also look like Aurinia is preparing itself to be acquired, an event that has been rumored consistently in recent years. An updated analysis around Aurinia Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaArtículo de análisis • Sep 06
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) shareholders have had their patience rewarded with a 30% share price jump...Seeking Alpha • Jul 05
Aurinia Pharmaceuticals Appears Undervalued
Summary Aurinia Pharmaceuticals stock has dropped more than 80% due to disappointing Lupkynis sales since its launch in 2021. Management is focusing solely on driving Lupkynis sales and cutting costs by laying off 25% of its sales force and discontinuing other programs. With positive cash flow expected soon, a $150 million share repurchase plan, and strong financials, Aurinia is undervalued and worth considering for investment. A full investment analysis around Aurinia Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaArtículo de análisis • May 24
We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Artículo de análisis • May 05
Analysts Have Made A Financial Statement On Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) First-Quarter Report
As you might know, Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) just kicked off its latest quarterly results with some...Seeking Alpha • May 02
Aurinia Pharma: A Welcome Change To The Thesis (Rating Upgrade)
Summary AUPH reports Q1'24 net product revenues of $48.1M, representing a 13.6% increase from the previous quarter. AUPH's pipeline member AUR200 has not been shelved and could enter phase 1 studies in 2024 whether in AUPH's hands, or externally if the drug is out-licensed. AUPH bought back 3.4M shares through April 30, at an average price of $5.37 per share. Read the full article on Seeking AlphaSeeking Alpha • Apr 18
Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024
Summary Aurinia Pharmaceuticals has the potential for up to 80-100% upside by the end of 2024. The company's focus on cost savings and a single product commercial biotech strategy is positive. The potential increase in US sales and from international markets paired with cost savings could make Aurinia cash flow positive by the end of the year. Future patent challenge to Lupkynis is likely, but defendable. Read the full article on Seeking AlphaSeeking Alpha • Mar 05
Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed
Summary AUPH's strategic review did not result in an acquisition of the company, nor the company acquiring an asset. AUPH has decided to buy back its own stock and focus on Lupkynis. The buyback could provide support for the stock near-term, although a return to strong sales growth would provide better support for the bull thesis. Read the full article on Seeking AlphaArtículo de análisis • Feb 19
Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report
There's been a major selloff in Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) shares in the week since it released its...Rentabilidad de los accionistas
| AUPH | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 4.7% | 6.2% | -0.8% |
| 1Y | 34.6% | 46.3% | 20.5% |
Rentabilidad vs. Industria: Los resultados de AUPH fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 46.3% el año pasado.
Rentabilidad vs. Mercado: AUPH superó al mercado US, que obtuvo un rendimiento del 20.5% el año pasado.
Volatilidad de los precios
| AUPH volatility | |
|---|---|
| AUPH Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: AUPH no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de AUPH (6%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1993 | 128 | Kevin Tang | www.auriniapharma.com |
Aurinia Pharmaceuticals Inc, empresa biofarmacéutica, se dedica a suministrar terapias a personas que padecen enfermedades autoinmunes con grandes necesidades médicas no cubiertas en Estados Unidos y Japón. La empresa ofrece LUPKYNIS (voclosporina), una terapia oral para el tratamiento de pacientes adultos con nefritis lúpica activa. También desarrolla aritinercept, un inhibidor dual del factor activador de células B y del ligando inductor de proliferación para el tratamiento potencial de enfermedades autoinmunes.
Resumen de fundamentos de Aurinia Pharmaceuticals Inc.
| Estadísticas fundamentales de AUPH | |
|---|---|
| Capitalización bursátil | US$2.04b |
| Beneficios(TTM) | US$314.11m |
| Ingresos (TTM) | US$311.51m |
6.8x
Ratio precio-beneficio (PE)6.9x
Ratio precio-ventas (PS)¿Está AUPH sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de AUPH | |
|---|---|
| Ingresos | US$311.51m |
| Coste de los ingresos | US$68.89m |
| Beneficio bruto | US$242.61m |
| Otros gastos | -US$71.50m |
| Beneficios | US$314.11m |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 2.36 |
| Margen bruto | 77.88% |
| Margen de beneficio neto | 100.84% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado AUPH a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/19 10:54 |
| Precio de las acciones al final del día | 2026/08/19 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Aurinia Pharmaceuticals Inc. está cubierta por 18 analistas. 7 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| David Martin | Bloom Burton & Co. |
| Dae Gon Ha | BTIG |
| Neil Maruoka | Canaccord Genuity |